Cyclosporine

• 

  Subject Areas on Research

  • 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 
  • A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation. 
  • A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. 
  • A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. 
  • A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients. 
  • A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study. 
  • A novel approach to the treatment of chronic allograft nephropathy. 
  • A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. 
  • A role for leukotrienes in cyclosporine nephrotoxicity. 
  • A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. 
  • Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. 
  • Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. 
  • Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. 
  • Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. 
  • Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day. 
  • An individual bioequivalence approach to compare the intrasubject variability of two ciclosporin formulations, SangCya and Neoral. 
  • An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. 
  • An intravitreal device providing sustained release of cyclosporine and dexamethasone. 
  • Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. 
  • Antifungal effects of cyclosporine and FK 506 are mediated via immunophilin-dependent calcineurin inhibition. 
  • Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method. 
  • Aplastic anaemia as an autoimmune complication of thymoma. 
  • Avascular necrosis following bone marrow transplantation: a case-control study. 
  • Bone density loss during treatment of chronic GVHD. 
  • Brequinar sodium potentiates the effects of cyclosporine in experimental small bowel transplantation. 
  • Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. 
  • CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. 
  • Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. 
  • Calcineurin is essential for survival during membrane stress in Candida albicans. 
  • Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains. 
  • Calcineurin is required for hyphal elongation during mating and haploid fruiting in Cryptococcus neoformans. 
  • Calcineurin is required for virulence of Cryptococcus neoformans. 
  • Calcineurin mediates pancreatic growth in protease inhibitor-treated mice. 
  • Calcineurin mutants render T lymphocytes resistant to cyclosporin A. 
  • Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. 
  • Calcineurin regulates cyclin D1 accumulation in growth-stimulated fibroblasts. 
  • Calcineurin. Structure, function, and inhibition. 
  • Cell biology. A fungal Achilles' heel. 
  • Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. 
  • Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus. 
  • Chronic kidney disease after hematopoietic cell transplantation: a systematic review. 
  • Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. 
  • Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. 
  • Clinical outcome of interval cadaveric renal transplantation in cardiac allograft recipients. 
  • Clinical trial of focal segmental glomerulosclerosis in children and young adults. 
  • Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. 
  • Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 
  • Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. 
  • Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. 
  • Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. 
  • Cryptococcus neoformans methionine synthase: expression analysis and requirement for virulence. 
  • Cyclosporin A inhibits chromium(VI)-induced apoptosis and mitochondrial cytochrome c release and restores clonogenic survival in CHO cells. 
  • Cyclosporin A inhibits inositol 1,4,5-trisphosphate binding to its receptors and release of calcium from intracellular stores in peritoneal macrophages. 
  • Cyclosporin A therapy for Wegener's granulomatosis. 
  • Cyclosporin A-related cerebral vasculopathy. 
  • Cyclosporin and asthma. 
  • Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation. 
  • Cyclosporine increases hepatocyte synthesis of the immunosuppressive free radical nitric oxide. 
  • Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. 
  • Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. 
  • Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 
  • Cytomegalovirus keratitis after penetrating keratoplasty. 
  • Delayed cardiac xenograft rejection in a pig-to-baboon model treated with a tolerance-inducing regimen and donor bone marrow infusion. 
  • Determination of the functional status of alloreactive T cells by interferon-gamma kinetics. 
  • Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 
  • Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? 
  • Dry eye medication use and expenditures: data from the medical expenditure panel survey 2001 to 2006. 
  • Effect of age and gender on the activity of human hepatic CYP3A. 
  • Effect of an intravitreal cyclosporine implant on experimental uveitis in horses. 
  • Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. 
  • Effect of cyclosporine on renal function in survivors of liver transplantation after 1 year. 
  • Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. 
  • Effect of surrogate tolerogenesis on the vascular rejection of pig heart xenografts. 
  • Effects of cyclosporine on human B-cell lymphoma development in vivo. 
  • Effects of immunosuppression and pretransplant splenectomy in newborn cardiac xenograft survival. 
  • Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity. 
  • Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 
  • Electrical stimulation of neonatal cardiac myocytes activates the NFAT3 and GATA4 pathways and up-regulates the adenylosuccinate synthetase 1 gene. 
  • Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. 
  • Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. 
  • Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. 
  • Evaluation of a delivery system providing long-term release of cyclosporine. 
  • Expression of heme oxygenase-1 can determine cardiac xenograft survival. 
  • FK 506 induction and rescue therapy in pancreas transplant recipients. 
  • FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. 
  • Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. 
  • HIV-1 infection: fooling the gatekeeper. 
  • Heart xenograft survival with chimeric pig donors and modest immune suppression. 
  • Hyperbaric oxygen and cyclosporine as a combined treatment regimen to prevent skin allograft rejection in immunohistoincompatible mice. 
  • Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. 
  • Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. 
  • Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 
  • Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. 
  • Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. 
  • Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. 
  • Implication of mitochondrial involvement in apoptotic activity of fragile histidine triad gene: application of synchronous luminescence spectroscopy. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 
  • Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: is prophylaxis necessary? 
  • Induction of T cell CD7 gene transcription by nonmitogenic ionomycin-induced transmembrane calcium flux. 
  • Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. 
  • Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 
  • Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. 
  • Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. 
  • Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. 
  • Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. 
  • LMP-420, a small molecular inhibitor of TNF-α, prolongs islet allograft survival by induction of suppressor of cytokine signaling-1: synergistic effect with cyclosporin-A. 
  • Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study. 
  • Late graft loss and long-term outcome after isolated intestinal transplantation in children. 
  • Late withdrawal of cyclosporine in stable renal transplant recipients. 
  • Living unrelated kidney donation: an underutilized resource? 
  • Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. 
  • Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. 
  • Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. 
  • Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. 
  • Management of childhood onset nephrotic syndrome. 
  • Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors. 
  • Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? 
  • Molecular cloning and characterization of Aspergillus nidulans cyclophilin B. 
  • Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. 
  • Mutations that perturb cyclophilin A ligand binding pocket confer cyclosporin A resistance in Saccharomyces cerevisiae. 
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 
  • Myristoylation of calcineurin B is not required for function or interaction with immunophilin-immunosuppressant complexes in the yeast Saccharomyces cerevisiae. 
  • Nerve activity-dependent modulation of calcineurin signaling in adult fast and slow skeletal muscle fibers. 
  • Novel motif in calcineurin catalytic subunit is required for septal localization of calcineurin in Aspergillus fumigatus. 
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. 
  • Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients. 
  • Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients. 
  • Pharmacotherapy for human immunodeficiency virus-associated nephropathy. 
  • Piceatannol in combination with low doses of cyclosporine A prolongs kidney allograft survival in a stringent rat transplantation model. 
  • Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. 
  • Potentiation of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506. 
  • Prevention of autoimmune islet allograft destruction by engraftment of donor T cells. 
  • Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. 
  • Progress in the treatment of rheumatoid arthritis. 
  • Prolonged discordant xenograft survival and delayed xenograft rejection in a pig-to-baboon orthotopic cardiac xenograft model. 
  • Prolyl isomerases in yeast. 
  • Quantitative proteomics approach for identifying protein-drug interactions in complex mixtures using protein stability measurements. 
  • R73A and H144Q mutants of the yeast mitochondrial cyclophilin Cpr3 exhibit a low prolyl isomerase activity in both peptide and protein-folding assays. 
  • Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells. 
  • Recipient Kupffer cell influx into xenografted liver. 
  • Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation. 
  • Regulation of tumor necrosis factor cytotoxicity by calcineurin. 
  • Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. 
  • Renal dysfunction in allogeneic hematopoietic cell transplantation. 
  • Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. 
  • Renal transplantation at the University of Wisconsin in the cyclosporine era. 
  • Renal transplantation in the cyclosporine era. 
  • Renal transplantation under FK 506 in African-Americans: early experience. 
  • Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. 
  • Retrospective analysis of the use of cyclosporine in myasthenia gravis. 
  • Review: implants. 
  • Risk factors for acute graft-versus-host disease associated with cyclosporine and methotrexate prophylaxis. 
  • SILAC-pulse proteolysis: A mass spectrometry-based method for discovery and cross-validation in proteome-wide studies of ligand binding. 
  • Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. 
  • Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. 
  • Should abdominal cluster transplantation be abandoned? 
  • Signal-transduction cascades as targets for therapeutic intervention by natural products. 
  • Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. 
  • Stable isotope labeling strategy for protein-ligand binding analysis in multi-component protein mixtures. 
  • StableIsotope Labeling with Amino Acids in Cell Culture (SILAC)-based strategy for proteome-wide thermodynamic analysis of protein-ligand binding interactions. 
  • Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides. 
  • Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. 
  • T cell CD7 mRNA expression is regulated by both transcriptional and post-transcriptional mechanisms. 
  • T cell activation up-regulates the expression of the focal adhesion kinase Pyk2: opposing roles for the activation of protein kinase C and the increase in intracellular Ca2+. 
  • T cells and macrophages responding to oxidative damage cooperate in pathogenesis of a mouse model of age-related macular degeneration. 
  • T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. 
  • Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. 
  • Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. 
  • Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. 
  • Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. 
  • Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. 
  • The natural history of renal function following orthotopic heart transplant. 
  • Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate. 
  • Thoracic organ transplantation at Papworth Hospital. 
  • Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. 
  • Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection. 
  • Treatment of Cyclosporin A retains host defense against invasive pulmonary aspergillosis in a non-immunosuppressive murine model by preserving the myeloid cell population. 
  • Treatment of pyoderma gangrenosum with cyclosporine. 
  • Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 
  • Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. 
  • Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. 
  • Use of protein phosphatase inhibitors. 
  • Use of protein phosphatase inhibitors. 
  • Vincristine therapy for severe platelet alloimmunization. 
  • Weaning of immunosuppression in liver transplant recipients. 
  • vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. 
• 

  Keywords of People

  • Middleton, John Paul, Associate Professor of Medicine, Medicine, Nephrology
  • Patz Jr., Edward F., James and Alice Chen Professor of Radiology, Pathology
  • Steinbach, William J., Samuel L. Katz Professor of Pediatrics, Duke Innovation & Entrepreneurship